Skip to main content

Advertisement

Table 1 Disease transition rates

From: Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Transition Mean SE Sources
F0 to F1 0.084 NA [17]
F1 to F2 0.092 NA
F2 to F3 0.145 NA
F3 to F4 0.116 NA
F4 (compensated cirrhosis) to decompensated cirrhosis 0.039 0.010 [20]
F4 (compensated cirrhosis) to HCC 0.014 0.010
Decompensated cirrhosis to HCC 0.014 0.010
Decompensated cirrhosis to liver transplant 0.030 0.012
Decompensated cirrhosis to death 0.130 0.010
HCC to liver transplant 0.030 0.012
HCC to death 0.430 0.030
Liver transplant (year 1) to death 0.210 0.046
Liver transplant (year 2+) to death 0.057 0.012
  1. HCC hepatocellular carcinoma, NA not applicable, SE standard error